Get the Stockscreener App
0.849
1.23%
-0.0106
Lexaria Bioscience Corp stock is traded at $0.849, with a volume of 62,712.
It is down -1.23% in the last 24 hours and down -19.14% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$0.8596
Open:
$0.87
24h Volume:
62,712
Relative Volume:
0.55
Market Cap:
$20.54M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.9295
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
-11.56%
1M Performance:
-19.14%
6M Performance:
-62.93%
1Y Performance:
-67.72%
1-Day Range:
$0.8289
$0.8889
1-Week Range:
$0.82
$1.0478
52-Week Range:
$0.82
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.849 | 20.54M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
LEXX: GLP-1-H25-5 Study Complete - Yahoo Finance
Lexaria Bioscience announces completion of GLP-1-H25-5 study - Yahoo Finance
Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results for Oral Liraglutide Study | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TradingView
GLP-1 Breakthrough: Oral Liraglutide Shows 67% Less Nausea in Clinical Trial | LEXX Stock News - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Trading Up 4.3% – Still a Buy? - Defense World
Lexaria Bioscience to Engage with Industry Leaders at BIO International Convention - TipRanks
Lexaria Attending BIO International Convention | LEXX Stock News - GuruFocus
Lexaria Attending BIO International Convention - TradingView
Lexaria Targets Weight Loss and Diabetes Partnerships at Massive BIO Convention with 20,000 Attendees - Stock Titan
Lexaria Bioscience stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Lexaria Bioscience stock hits 52-week low at $0.94 - Investing.com
Lexaria Bioscience Corp (NASDAQ: LEXX) Is Down -15.79% Since Its Low, And It’s Only Getting Started. - Stocksregister
Lexaria advances drug delivery tech with PharmaCO By Investing.com - Investing.com Nigeria
Raymond James Financial Inc. Makes New Investment in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria (LEXX) Advances Collaborative Pharmaceutical Research | - GuruFocus
Lexaria Advances Collaboration with Pharma Partner on Drug Delivery Technology - TipRanks
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - marketscreener.com
Lexaria Provides Update on Material Transfer Agreement with Phar - GuruFocus
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience stock hits 52-week low at $1.14 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com Australia
Lexaria Announces Closing of $2 Million Registered Direct Offeri - GuruFocus
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Yahoo Finance
Lexaria Bioscience Secures $2 Million in Direct Stock Offering - TipRanks
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Market Watch Highlights: Lexaria Bioscience Corp (LEXX) Ends on an Downturn Note at 1.35 - DWinneX
Lexaria Bioscience Corp (LEXX) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
What is Zacks Small Cap’s Estimate for LEXX FY2025 Earnings? - Defense World
Lexaria Bioscience (LEXX) Announces $2M Direct Offering | LEXX S - GuruFocus
Lexaria Bioscience Secures $2 Million in Registered Direct Stock Offering - citybuzz -
Lexaria Announces $2 Million Registered Direct Offering of Commo - GuruFocus
Lexaria Bioscience secures $2 million in direct offering By Investing.com - Investing.com South Africa
Lexaria Bioscience secures $2 million in direct offering - Investing.com
Lexaria Announces $2 Million Registered Direct Offering of Common Stock - TradingView
Lexaria Lands $2M Strategic Investment: Institutional Investor Backs Biotech at $1.00 Per Share - Stock Titan
Lexaria Bioscience (OTCMKTS:LXRP) versus U.S. Gold (NASDAQ:USAU) Critical Comparison - Defense World
LEXXLexaria Bioscience Corp Latest Stock News & Market Updates - Stock Titan
LEXX: Second Quarter Results - Yahoo Finance
Lexaria Bioscience (LEXX) Advances in GLP-1 Technology Amid Indu - GuruFocus
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
| TURKEL CATHERINE C. | Director |
Aug 12 '24 |
Buy |
3.13 |
1,600 |
5,008 |
3,100 |
| Carle Vanessa | Secretary |
Jul 31 '24 |
Sale |
4.00 |
2,567 |
10,268 |
0 |
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):